[{"author":"JohnHuber72","content":"@ojaz12 @afc The huge returns have mostly come from revenue growth. SHOP\u2019s multiple is only 1.33x higher than IPO,\u2026 https:\/\/t.co\/esOp1mdwVI","pubdate":"20190716022310","NumFavorite":4,"NumShare":0,"CrawlerDate":20200720},{"author":"JohnHuber72","content":"@oddballstocks Hmmm... I didn\u2019t really see that at all Nate. He was just laying out facts on the historical perform\u2026 https:\/\/t.co\/SpmOoRxELp","pubdate":"20190716023131","NumFavorite":19,"NumShare":0,"CrawlerDate":20200720},{"author":"JohnHuber72","content":"@ojaz12 @afc I think the question for SaaS industry generally is what do normal economics look without VC subsidies\u2026 https:\/\/t.co\/fKhgWvX2LJ","pubdate":"20190716023927","NumFavorite":4,"NumShare":0,"CrawlerDate":20200720},{"author":"FundyLongShort","content":"@WTCM3 Excellent, thanks for posting.","pubdate":"20190716134226","NumFavorite":1,"NumShare":0,"CrawlerDate":20200720},{"author":"KerrisdaleCap","content":"We\u2019re short $CDNA. Report available at https:\/\/t.co\/HHxiIuc8Jt. Conf call at 1pm, dial 866-834-3313, #2995924. Care\u2026 https:\/\/t.co\/8VatEh71LK","pubdate":"20190716135836","NumFavorite":21,"NumShare":12,"CrawlerDate":20200720},{"author":"KerrisdaleCap","content":"AlloSure sales is overwhelmingly comprised of usage in clinical studies designed to test the product's effectivenes\u2026 https:\/\/t.co\/9D03EMfLiV","pubdate":"20190716135912","NumFavorite":0,"NumShare":0,"CrawlerDate":20200720},{"author":"KerrisdaleCap","content":"Trials show that AlloSure misses &gt;40% of rejections identified by the current standard of care, making it dangerous\u2026 https:\/\/t.co\/K8cVvozmW9","pubdate":"20190716135943","NumFavorite":0,"NumShare":0,"CrawlerDate":20200720},{"author":"KerrisdaleCap","content":"Patient attrition rates are a staggering 25% *per quarter* and new patient enrollment has peaked. This points to de\u2026 https:\/\/t.co\/GbG1OlkCfe","pubdate":"20190716140012","NumFavorite":0,"NumShare":0,"CrawlerDate":20200720},{"author":"KerrisdaleCap","content":"Poor results expose AlloSure to competition in H2. Natera\u2019s Prospera test is set to enter the market, partnering w\/\u2026 https:\/\/t.co\/yRXtwoP8U3","pubdate":"20190716140027","NumFavorite":0,"NumShare":0,"CrawlerDate":20200720},{"author":"KerrisdaleCap","content":"Finally, the studies showing AlloSure\u2019s extremely limited clinical utility will affect the parameters of permanent\u2026 https:\/\/t.co\/1wuUBDYDLR","pubdate":"20190716140051","NumFavorite":2,"NumShare":0,"CrawlerDate":20200720},{"author":"KerrisdaleCap","content":"At 18x trailing revenue, and 33x the most recent quarter\u2019s AlloSure run-rate, CareDx\u2019s valuation is even richer tha\u2026 https:\/\/t.co\/s1JqkRones","pubdate":"20190716140106","NumFavorite":1,"NumShare":3,"CrawlerDate":20200720},{"author":"KerrisdaleCap","content":"@AnthonyTsaiPPro Eastern","pubdate":"20190716175416","NumFavorite":0,"NumShare":0,"CrawlerDate":20200720},{"author":"xuexishenghuo","content":"2 done, 1 to go https:\/\/t.co\/9OqOaZt5JS","pubdate":"20190716211722","NumFavorite":3,"NumShare":0,"CrawlerDate":20200720},{"author":"xuexishenghuo","content":"@AlderLaneeggs He is the best","pubdate":"20190716211924","NumFavorite":1,"NumShare":0,"CrawlerDate":20200720},{"author":"xuexishenghuo","content":"@AlderLaneeggs But but but if you don\u2019t like the idea of predators selling crap to poor people, you could be a racist","pubdate":"20190716213652","NumFavorite":2,"NumShare":0,"CrawlerDate":20200720}]